SCHEMBL3247467

SCHEMBL3247467

COc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2Cc2ccccc2Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
KEAP1 Q14145 5/20 0.54
NFE2L2 Q16236 3/20 0.54
SQSTM1 Q13501 1/20 0.54
CCR9 P51686 1/20 0.53
KDR P35968 2/20 0.52
GAA P10253 2/20 0.49
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
KMT2A Q03164 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
MITF O75030 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
CASP1 P29466 1/20 0.48
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247458 0.89 KEAP1 (0.58) LMNAKEAP1NFE2L2KDRFLT1
SCHEMBL3253721 0.84 TSHR (0.48) CCR9KDRGAAFLT1FLT4
SCHEMBL3252007 0.82 TSHR (0.58) KMT2AALDH1A1CASP1SMN1; SMN2HSD17B10
SCHEMBL3256105 0.79 ALDH1A1 (0.65) LMNAKEAP1NFE2L2KMT2AALDH1A1
SCHEMBL3250123 0.77 MAPK1 (0.60) LMNAKEAP1NFE2L2GAAKMT2A
SCHEMBL2616513 0.76 LMNA (0.63) LMNAKEAP1NFE2L2SQSTM1CCR9
SCHEMBL3251866 0.76 KEAP1 (0.53) KEAP1NFE2L2KDRGAAFLT1
SCHEMBL3247611 0.75 TSHR (0.46) LMNAKDRGAAFLT1FLT4
SCHEMBL27857 0.75 LMNA (0.77) LMNACCR9KMT2AALDH1A1TP53
SCHEMBL4863945 0.74 TSHR (0.60) GAAKMT2AALDH1A1TP53CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 LMNA 3046/4885KEAP1 3317/4885NFE2L2 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.